Christiaan Scott

ORCID: 0000-0003-3874-1704
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Autoimmune and Inflammatory Disorders Research
  • Adolescent and Pediatric Healthcare
  • Systemic Lupus Erythematosus Research
  • Kawasaki Disease and Coronary Complications
  • Child and Adolescent Health
  • Heterotopic Ossification and Related Conditions
  • Medical Imaging and Pathology Studies
  • Immunodeficiency and Autoimmune Disorders
  • Musculoskeletal Disorders and Rehabilitation
  • Rheumatoid Arthritis Research and Therapies
  • Inflammasome and immune disorders
  • Family and Disability Support Research
  • Parathyroid Disorders and Treatments
  • COVID-19 Clinical Research Studies
  • Inflammatory Myopathies and Dermatomyositis
  • Pharmaceutical studies and practices
  • Vasculitis and related conditions
  • Childhood Cancer Survivors' Quality of Life
  • Atherosclerosis and Cardiovascular Diseases
  • Genetic Syndromes and Imprinting
  • interferon and immune responses
  • Immune Cell Function and Interaction
  • SARS-CoV-2 and COVID-19 Research
  • Coronary Artery Anomalies
  • COVID-19 Impact on Reproduction

University of Cape Town
2016-2025

University of Ottawa
2024-2025

Children's Hospital of Eastern Ontario
2024-2025

Great Ormond Street Hospital for Children NHS Foundation Trust
2023-2024

Red Cross War Memorial Children's Hospital
2015-2024

Leiden University Medical Center
2024

Groote Schuur Hospital
2011-2023

Lewis Gale Medical Center
2023

Western Cape Department of Health
2022

Stellenbosch University
2022

Recent therapeutic advances in juvenile idiopathic arthritis (JIA) have made remission an achievable goal for most patients. Reaching this target leads to improved outcomes. The objective was develop recommendations treating JIA target. A Steering Committee formulated a set of based on evidence derived from systematic literature review. These were subsequently discussed, amended and voted by international Task Force 30 paediatric rheumatologists consensus-based, Delphi-like procedure....

10.1136/annrheumdis-2018-213030 article EN Annals of the Rheumatic Diseases 2018-04-11

BACKGROUNDUndifferentiated systemic autoinflammatory diseases (USAIDs) present diagnostic and therapeutic challenges. Chronic interferon (IFN) signaling cytokine dysregulation may identify with available targeted treatments.METHODSSixty-six consecutively referred USAID patients underwent screening for the presence of an signature using a standardized type-I IFN-response-gene score (IRG-S), profiling, genetic evaluation by next-generation sequencing.RESULTSThirty-six (55%) had elevated IRG-S....

10.1172/jci129301 article EN Journal of Clinical Investigation 2019-12-24

Objective. Rituximab, an anti-CD20 monoclonal antibody, has been used in lupus nephritis and membranous idiopathic nephropathy proved effective non-renal manifestations of type II mixed cryoglobulinaemia (MC) syndrome. We investigated the possible efficacy safety rituximab treatment cryoglobulinaemic nephritis.

10.1093/rheumatology/kel004 article EN Lara D. Veeken 2006-01-17

Treatment options in patients with enthesitis-related arthritis (ERA) and juvenile psoriatic (JPsA) are currently limited. This trial aimed to demonstrate the efficacy safety of secukinumab active ERA JPsA inadequate response conventional therapy.In this randomised, double-blind, placebo-controlled, treatment-withdrawal, phase 3 trial, biologic-naïve (aged 2 <18 years) disease were treated open-label subcutaneous (75/150 mg <50/≥50 kg) treatment period (TP) 1 up week 12, idiopathic (JIA)...

10.1136/ard-2022-222849 article EN cc-by Annals of the Rheumatic Diseases 2022-08-12

Juvenile idiopathic arthritis (JIA) is a disease that shows wide variations between differing populations. Since the recent international consensus on classification criteria, JIA has been widely described in many countries and population groups. There almost no data describes an African, specifically Sub-Saharan setting. Therefore, aim of this study to describe characteristics, course, functional disability two tertiary centres Western Cape, South Africa compare findings other Eighty-six...

10.1186/1546-0096-10-35 article EN cc-by Pediatric Rheumatology 2012-10-10

Background Systemic lupus erythematosus (SLE) is a life-threatening multisystem autoimmune disease that more severe in patients of African ancestry and children, yet pediatric SLE on the continent has been understudied. This study describes cohort (PULSE) South Africa. Methods Patients with diagnosis (1997 American College Rheumatology criteria) diagnosed prior to age 19 years Cape Town, Africa, were enrolled this cross-sectional from September 2013 December 2014. Information clinical...

10.1177/0961203316660625 article EN Lupus 2016-08-04

Abstract Background Multisystem inflammatory syndrome is a severe manifestation of SARS-CoV-2 in children. The incidence MIS-C after infection poorly understood. There are very few cohorts describing Africa despite being more common Black children worldwide. Methods A cohort with and healthy was recruited from May 2020 until 2021 the two main paediatric hospitals Cape Town, South Africa. Clinical demographic data were collected, serum tested for antibodies. calculated using an estimation...

10.1186/s12887-022-03308-z article EN cc-by BMC Pediatrics 2022-05-02

Juvenile dermatomyositis (JDM) is a rare idiopathic inflammatory childhood myopathy of uncertain aetiology. The demographic and clinical presentation JDM may differ by race geographic regions. Few studies have described the characteristics patients from Africa. We conducted retrospective observational study to determine outcomes satisfying Bohan Peter criteria for probable seen between 2004 2013 in three hospitals Cape Town, South Twenty five cases were identified: 16 female 9 male; thirteen...

10.1186/s12969-016-0118-0 article EN cc-by Pediatric Rheumatology 2016-11-11

To assess efficacy, pharmacokinetics (PK) and safety of intravenous (i.v.) golimumab in patients with polyarticular-course JIA (pc-JIA).Children aged 2 to <18 years active pc-JIA despite MTX therapy for ≥2 months received 80 mg/m2 at weeks 0, 4, then every 8 through week 52 plus weekly 28. The primary major secondary endpoints were PK exposure model-predicted steady-state area under the curve (AUCss) over an 8-week dosing interval 28 52, respectively. ACR response also assessed.In total, 127...

10.1093/rheumatology/keab021 article EN cc-by-nc Lara D. Veeken 2021-01-15

The effects of SARS-CoV-2 variants on disease phenotype and severity multisystem inflammatory syndrome in children (MIS-C) are unknown. We compared the clinical MIS-C 129 South African across four distinct (Ancestral type, Beta, Delta, Omicron) variant-driven waves found that remains a severe with stable presentation, regardless variant.

10.1097/inf.0000000000003691 article EN The Pediatric Infectious Disease Journal 2022-09-05

Multisystem inflammatory syndrome in children (MIS-C) is a disease that occurs after exposure to severe acute respiratory coronavirus 2 (SARS-CoV-2). Its short-term effects have been documented but little data exist on the longer term of MIS-C health and quality life (QOL) patients. The objective this study was assess long-term QOL children. This descriptive prospective study. We included 24 participants with previous 20 juvenile idiopathic arthritis (JIA) as positive comparator group. All...

10.3389/fped.2024.1465976 article EN cc-by Frontiers in Pediatrics 2025-01-28
Coming Soon ...